Mediated Delivery of Nanocarriers to the Brain

A distinct case of the vehicle-mediated CNS drug delivery employs specific cells carriers that can incorporate micro- and 

T lymphocytes were also proposed as a potential therapeutic drug carriers for cancer treatment (Steinfeld et al., 2006). The kinetics of loading and release of nanoparticles coated with cytotoxic antibiotic Dox into the cells were examined. It was suggested that the immune cells can accomplish target-specific and sheltered transport to the diseased site. 

Ability of host cells to home diseased sites after ex vivo manipulation is a fundamental requirement and a major problem for their use as vehicles to target locally acting gene therapy to specific diseased sites. It was demonstrated that in the short term, up to 2 h after re-implantation, macrophages accumulate primarily in the lungs and, to a lesser extent, in the liver and spleen rather than in the target diseased tissue. A small proportion of 

Recently, a new class of inhibitors (nonionic polymer surfactants) was identified as a promising component of drug 

Pluronic P85 EO26-PO40-EO26 MW = 4600 Pluronic F127 EOioo-POs5-EOioo MW = 12600 

---